Daniel Alkon

Dr. Daniel Alkon, the chief scientific officer at Neurotrope Inc (NASDAQ: NTRP), discussed the fight against Alzheimer's disease in an interview with Benzinga.  Benzinga: What is bryostatin, and how is it used for the treatment in patients with moderate to severe Alzheimer's disease?...

A biotech company making a jump from the OTC market to the Nasdaq is certainly not as difficult as finding a cure for Alzheimer’s Disease. However, OTC investors are well aware that up-listings are a rare phenomenon. Neurotrope Inc (NASDAQ: NTRP) investors are hoping that the company’s...